David Goel’s Moderna MRNA Stock Holding History

David Goel’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-730,000	Closed	-$77.8M	–	24
2024 Q1	$77.8M	Buy	730,000 +276,000	+61%	+$27.8M	0.72%	13
2023 Q4	$45.2M	Buy	+454,000	New	+$38.2M	0.46%	15

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

David Goel's MRNA Position: Q2 2024 in Review

David Goel sold out of Moderna (MRNA) in Q2 2024, closing a stake of 730,000 shares — an estimated $77.8M sold.

David Goel first reported a position in MRNA in Q4 2023 and held it in 2 quarters. The position peaked at $77.8M in Q1 2024. 955 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

David Goel reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
David Goel sold 730,000 Moderna shares in Q2 2024, an estimated $77.8M.
David Goel first reported a position in Moderna in Q4 2023 and held it in 2 quarters.
David Goel's Moderna position peaked at $77.8M in Q1 2024.
955 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Matrix Capital Management Company's 13F filing for Q2 2024, filed 14 Aug 2024.